Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)

D. Peereboom; L. B. Nabors; P. Kumthekar; M. Badruddoja; K. Fink; F. Lieberman; S. Phuphanich; E. Dunbar; T. Walbert; D. Schiff; D. D. Tran; L. S. Ashby; N. Butowski; F. Iwamoto; R. Lindsay; J. Bullington; M. Schulder; J. Sherman; C. Brooks; D. Reardon

doi:10.1093/annonc/mdy273.361

Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)

D. Peereboom, L. B. Nabors, P. Kumthekar, M. Badruddoja, K. Fink, F. Lieberman, S. Phuphanich, E. Dunbar, T. Walbert, D. Schiff, D. D. Tran, L. S. Ashby, N. Butowski, F. Iwamoto, R. Lindsay, J. Bullington, M. Schulder, J. Sherman, C. Brooks, D. Reardon

Neurology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii122-viii123
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy273.361
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy273.361

Cite this

Peereboom, D., Nabors, L. B., Kumthekar, P., Badruddoja, M., Fink, K., Lieberman, F., Phuphanich, S., Dunbar, E., Walbert, T., Schiff, D., Tran, D. D., Ashby, L. S., Butowski, N., Iwamoto, F., Lindsay, R., Bullington, J., Schulder, M., Sherman, J., Brooks, C., & Reardon, D. (2018). Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii122-viii123. https://doi.org/10.1093/annonc/mdy273.361

@article{79cde0008459452e868ca5636cac3541,

title = "Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)",

author = "D. Peereboom and Nabors, {L. B.} and P. Kumthekar and M. Badruddoja and K. Fink and F. Lieberman and S. Phuphanich and E. Dunbar and T. Walbert and D. Schiff and Tran, {D. D.} and Ashby, {L. S.} and N. Butowski and F. Iwamoto and R. Lindsay and J. Bullington and M. Schulder and J. Sherman and C. Brooks and D. Reardon",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy273.361",

language = "English (US)",

volume = "29",

pages = "viii122--viii123",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

Peereboom, D, Nabors, LB, Kumthekar, P, Badruddoja, M, Fink, K, Lieberman, F, Phuphanich, S, Dunbar, E, Walbert, T, Schiff, D, Tran, DD, Ashby, LS, Butowski, N, Iwamoto, F, Lindsay, R, Bullington, J, Schulder, M, Sherman, J, Brooks, C & Reardon, D 2018, 'Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii122-viii123. https://doi.org/10.1093/annonc/mdy273.361

Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM). / Peereboom, D.; Nabors, L. B.; Kumthekar, P. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii122-viii123.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)

AU - Peereboom, D.

AU - Nabors, L. B.

AU - Kumthekar, P.

AU - Badruddoja, M.

AU - Fink, K.

AU - Lieberman, F.

AU - Phuphanich, S.

AU - Dunbar, E.

AU - Walbert, T.

AU - Schiff, D.

AU - Tran, D. D.

AU - Ashby, L. S.

AU - Butowski, N.

AU - Iwamoto, F.

AU - Lindsay, R.

AU - Bullington, J.

AU - Schulder, M.

AU - Sherman, J.

AU - Brooks, C.

AU - Reardon, D.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081530695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081530695&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy273.361

DO - 10.1093/annonc/mdy273.361

M3 - Article

C2 - 32136161

SN - 0923-7534

VL - 29

SP - viii122-viii123

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Peereboom D, Nabors LB, Kumthekar P, Badruddoja M, Fink K, Lieberman F et al. Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii122-viii123. doi: 10.1093/annonc/mdy273.361

Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this